Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
karaya gum + ctenocephalides canis + ctenocephalides felis + acacia + tragacanth
- Development stage
- Approved
- Lead developer
- Nelco Laboratories
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Parenteral
01
Overview
This product is a **combination allergenic extract injectable solution** containing karaya gum, **Ctenocephalides canis** extract, **Ctenocephalides felis** extract, acacia, and tragacanth, formulated for allergen-specific immunotherapy and diagnostic allergy practice. It is a **biologic allergen extract** used in patients with demonstrated sensitization to these allergens, with use cases that include diagnosis and treatment of allergen-specific allergic disease when supported by allergy history and reactivity testing. Its therapeutic effect is not mediated through a conventional single molecular target; rather, repeated administration is intended to modulate the patient's **IgE-mediated hypersensitivity** and broader adaptive immune response to the included allergens, consistent with hyposensitization or allergy shot practice. The product is associated with NDC 36987-1646 and has been manufactured by Jubilant HollisterStier.
- Other names
- karaya gum + ctenocephalides canis + ctenocephalides felis + acacia + tragacanthallergenic extract karaya gum + ctenocephalides canis + ctenocephalides felis + acacia + tragacanthkaraya gum, dog flea, cat flea, acacia, tragacanth allergenic extract
02
Targets
A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)
Beyond the preview
Go deeper on karaya gum + ctenocephalides canis + ctenocephalides felis + acacia + tragacanth.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on karaya gum + ctenocephalides canis + ctenocephalides felis + acacia + tragacanth.